Introduction {#s1}
============

The α-glucosidase inhibitors (AGIs) are commonly prescribed oral antidiabetic drugs (OADs) for patients with type 2 diabetes mellitus (T2DM), particularly for the Asian patients ([@B4]; [@B9]; [@B15]). In China, AGIs are recommended as the second-line therapy for T2DM if optimal glycemic control could not be achieved by the first-line therapy of metformin ([@B37]; [@B1]). Acting as inhibitors of α-glucosidase located in the brush border of the small intestine, AGIs reduce postprandial glucose (PPG) level *via* attenuating the digestion of carbohydrates, with an increased incidence of gastrointestinal side effects ([@B38]; [@B9]). The dipeptidyl peptidase-4 (DPP4) inhibitors are a novel category of OADs which inhibit the inactivation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) ([@B3]). It is suggested that DPP4 inhibitors may improve glycemic control with less risk of gastrointestinal adverse side effects compared to AGIs. However, results of previously randomized controlled trials (RCTs) were not consistent ([@B30]; [@B13]; [@B14]; [@B32]; [@B16]; [@B29]; [@B17]; [@B22]; [@B26]; [@B28]; [@B36]; [@B39]; [@B8]; [@B21]; [@B25]; [@B5]; [@B18]; [@B31]). Therefore, we performed a meta-analysis for the head-to-head comparison of the hypoglycemic efficacy and safety outcomes between DPP4 inhibitors and AGIs in patients with T2DM.

Materials and Methods {#s2}
=====================

This meta-analysis was designed, performed, and presented in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement ([@B23]) and Cochrane's Handbook guideline ([@B11]).

Database Search {#s2_1}
---------------

We performed the initial electronic database search of the PubMed, Embase, and Cochrane's Library from inception to February, 2019, *via* the combination of the following terms: 1) "DDP4" OR "DDP-4" OR "DPP4 inhibitors" OR "sitagliptin" OR "vildagliptin" OR "linagliptin" OR "saxagliptin" OR "alogliptin" OR "dutogliptin," 2) "alpha-GIs" OR "alpha-glucosidase inhibitors" OR "acarbose" OR "voglibose" OR "miglitol," and 3) "random" OR "randomly" OR "randomized" OR "randomised." The search was limited to studies in human, and no restriction was applied for the language of publication. The final literature search was performed on February 12th, 2019.

Inclusion and Exclusion Criteria {#s2_2}
--------------------------------

Studies were included if they met the following criteria: 1) designed as a parallel group RCT; 2) included adult patients with T2DM; 3) allocated to an intervention group of oral DPP4 inhibitor and a control group of AGI, with or without coadministration of other oral antidiabetic medications, such as metformin and/or sulfonylureas et al.; 4) with a follow-up duration of at least 8 weeks; and 5) reported at least one of the following outcomes: changes of glycosylated hemoglobin (HbA1c), fasting blood glucose (FBG), PPG at 2h, and body weight from baseline, and the incidences of symptomatic hypoglycemia and any gastrointestinal adverse events (GIAEs) in patients of both groups. Reviews, crossover trials, preclinical studies in animals, and repeated reports of already included RCTs were excluded.

Data Extraction and Quality Evaluation {#s2_3}
--------------------------------------

We extracted the following study characteristics of each RCT: 1) location of the study; 2) design characteristics: single-blind, double-blind, or open label; 3) patients' characteristics: number, age, gender, baseline HbA1c, body mass index (BMI); 4) details of background OADs; 5) regimens of DPP4 inhibitors and AGIs; and 6) follow-up durations. The quality of the included RCT was evaluated by the Cochrane's risk of bias tool ([@B11]), which is based on the following seven domains: random sequence generation, allocation concealment, blinding in performance, blinding in outcome detection, incomplete outcome data, reporting bias, and the potential risk of other bias. The processes of database search, study identification, data extraction, and quality evaluation were independently performed by two authors. Discussion with a third author was indicated when discrepancies occurred.

Statistical Analyses {#s2_4}
--------------------

The statistical analyses were performed with RevMan software (version 5.1; Cochrane Collaboration, Oxford, UK) and Stata software (version 12.0; Stata Corporation, College Station, TX). Continuous variables were analyzed using weighed mean difference (WMD) and 95% confidence interval (CI), while categorized variables were analyzed using risk ratio (RR) and 95% CI. The heterogeneity among the included RCTs was evaluated by the Cochrane's *Q* test ([@B11]) and a *P* \< 0.10 indicating significant heterogeneity. We also used *I* ^2^ statistic, which describes the percentage of total variation across studies that is due to heterogeneity rather than chance ([@B12]), as an indicator of heterogeneity, and an *I* ^2^ \> 50% indicates significant heterogeneity. A fixed effect model was used to pool the results of individual study during meta-analysis, if the heterogeneity was not significant according to the results of the Cochrane's *Q* test; otherwise, a random effect model was applied ([@B20]). The primary outcome of the study was the difference of changes of HbA1c between patients treated with DPP4 inhibitors and AGIs. Predefined subgroup analyses were performed to evaluate the potential influence of study characteristics including blinding, number of patients, baseline HbA1c, with or without background OADs, follow-up durations, and individual drugs of DPP4 inhibitor or AGI applied on the primary outcome. Medians of the continuous variables were used as cutoff value for stratification in subgroup analyses ([@B24]). The potential publication bias for the meta-analysis of each outcome was evaluated by the visual inspection of the symmetry of the funnel plots, as well as the Egger's regression test ([@B6]). A *P* value \< 0.05 indicates statistical significance.

Results {#s3}
=======

Database Search Result {#s3_1}
----------------------

The process of database search was summarized in [**Figure 1**](#f1){ref-type="fig"}. Briefly, 450 studies were obtained *via* the initial database search, and 415 studies were excluded based on analyses of titles and abstracts, mostly because these studies were irrelevant to current study objective. Of the remaining 35 studies that underwent full-text review, 17 studies were excluded because two of them did not include T2DM patients, two evaluated a combined effect of DPP4 inhibitors and AGIs, six were with follow-up durations \<8 weeks, three were subgroup or extension studies of included RCTs, two were not with available outcome data, and another two were repeated reports of the included RCTs. Finally, 18 RCTs were included ([@B30]; [@B13]; [@B14]; [@B32]; [@B16]; [@B29]; [@B17]; [@B22]; [@B26]; [@B28]; [@B36]; [@B39]; [@B8]; [@B21]; [@B25]; [@B5]; [@B18]; [@B31]).

![Flowchart of database search and study identification of the meta-analysis.](fphar-10-00777-g001){#f1}

Study Characteristics and Quality Evaluation {#s3_2}
--------------------------------------------

Overall, our meta-analysis included 18 RCTs ([@B30]; [@B13]; [@B14]; [@B32]; [@B16]; [@B29]; [@B17]; [@B22]; [@B26]; [@B28]; [@B36]; [@B39]; [@B8]; [@B21]; [@B25]; [@B5]; [@B18]; [@B31]) with a total of 4,051 T2DM patients. Since two studies included more than one intervention groups with different dosages of DPP4 inhibitors ([@B32]; [@B16]), we split the control group of AGI equally and included these datasets with different dosages of DPP4 inhibitors as independent comparisons into the meta-analysis, as indicated by the Cochrane's Handbook guideline ([@B11]). Therefore, 22 comparisons of the efficacy between DPP4 inhibitors and AGIs in T2DM patients were included in our meta-analysis. The characteristics of included RCTs were summarized in [**Table 1**](#T1){ref-type="table"}. All of the included RCTs were published after 2008, and included T2DM patients from Japan and China except for one study which also included a small proportion of patients (\<10%) from Romania and Spain ([@B30]). The sample sizes of the included studies varied from 16 to 661, with the mean ages varying from 49.7 to 97.5 years, and proportions of males ranging between 38.3 and 78.5%. The mean baseline HbA1c was 6.0∼8.6%, and the mean BMI was 21.5∼29.2 kg/m^2^. Nine RCTs included patients of initial therapy without background OADs ([@B30]; [@B13]; [@B14]; [@B32]; [@B16]; [@B25]; [@B5]; [@B18]; [@B31]), while the other 13 RCTs compared the efficacy between DPP4 inhibitors and AGIs on the basis of background OADs ([@B29]; [@B17]; [@B22]; [@B26]; [@B28]; [@B36]; [@B39]; [@B8]; [@B21]). Five DPP4 inhibitors (alogliptin, linagliptin, saxagliptin, sitagliptin, and vildagliptin) and three AGIs (acarbose, miglitol, and voglibose) were applied respectively in the included RCTs, with the regularly recommended doses. The follow-up durations varied from 10 to 52 weeks. The details of quality evaluation for the included RCTs were summarized in [**Table 2**](#T2){ref-type="table"}. Overall, the quality of the included RCTs was moderate. Briefly, six of the included studies were double-blinded RCTs ([@B30]; [@B13]; [@B14]; [@B32]; [@B16]; [@B31]), while the other 16 were open label studies ([@B29]; [@B17]; [@B22]; [@B26]; [@B28]; [@B36]; [@B39]; [@B8]; [@B21]; [@B25]; [@B5]; [@B18]). Six studies reported the methods of random sequence generation ([@B14]; [@B17]; [@B28]; [@B39]; [@B21]; [@B25]). However, none of them reported the details of allocation concealment.

###### 

Characteristics of the included studies.

  Study        Country                     Design   Sample size   Mean age   Male   HbA1c   BMI       Background OADs                            Dpp4 inhibitors                           AGI                                          Follow-up
  ------------ --------------------------- -------- ------------- ---------- ------ ------- --------- ------------------------------------------ ----------------------------------------- -------------------------------------------- -----------
                                                                  Years      \%     \%      kg/m^2^                                                                                                                                     Weeks
  [@B30]       China, Romania, and Spain   R, DB    661           51.9       61.2   8.6     26.3      None                                       Vildagliptin 50 mg bid                    Acarbose 50∼100 mg tid                       24
  [@B13]       Japan                       R, DB    319           60.7       66.5   7.8     24.6      None                                       Sitagliptin 50 mg qd                      Voglibose 0.2 mg tid                         12
  [@B14]       Japan                       R, DB    380           59.1       66.1   7.6     24.9      None                                       Vildagliptin 50 mg bid                    Voglibose 0.2 mg tid                         12
  [@B32] ^1^   Japan                       R, DB    480           58.9       71.9   7.9     24.7      None                                       Alogliptin 6.25, 12.5, 25, and 50 mg qd   Voglibose 0.2 mg tid                         52
  [@B16] ^2^   Japan                       R, DB    481           59.8       70.4   8       25.1      None                                       Linagliptin 5 mg, 10 mg qd                Voglibose 0.2 mg tid                         26
  [@B29]       Japan                       R        35            65.6       38.3   7.8     24.4      Sulfonylurea                               Sitagliptin 50 mg qd                      Miglitol 50 mg tid                           10
  [@B26]       Japan                       R        55            67.5       50.9   7       26.6      Sulfonylurea, metformin, or pioglitazone   Sitagliptin 50 mg qd                      Voglibose 0.2 mg tid                         12
  [@B17]       Japan                       R        114           64.2       61.5   7.6     24.3      Sulfonylurea                               Sitagliptin 50 mg qd                      Voglibose 0.2 mg tid or miglitol 50 mg tid   24
  [@B22]       Japan                       R        28            59         78.5   7.2     29.2      Metformin or sulfonylurea                  Sitagliptin 50 mg qd                      Miglitol 50 mg tid                           24
  [@B28]       Japan                       R        80            67.2       57.5   7       26.7      Sulfonylurea, metformin, or pioglitazone   Sitagliptin 50 mg qd                      Voglibose 0.2 mg tid                         24
  [@B36]       China                       R        81            64.6       46.3   8.3     NA        Metformin                                  Saxagliptin 5 mg qd                       Acarbose 50 mg tid                           52
  [@B39]       Japan                       R        119           58.5       63.8   7.6     26.1      Metformin or pioglitazone                  Sitagliptin 50 mg qd                      Voglibose 0.2 mg tid or miglitol 50 mg tid   24
  [@B25]       Japan                       R        78            67.2       78.2   6.6     21.5      None                                       Linagliptin 5 mg qd                       Voglibose 0.2 mg tid                         12
  [@B21]       Japan                       R        241           63.2       59.3   7.9     25        Sulfonylurea, metformin, or pioglitazone   Sitagliptin 50 mg qd                      Voglibose 0.2 mg tid                         12
  [@B8]        Japan                       R        382           61         55.1   7       25.4      None                                       Linagliptin 5 mg qd                       Voglibose 0.2 mg tid                         12
  [@B5]        China                       R        481           55.6       59.3   8.2     26.3      Metformin                                  Saxagliptin 5 mg qd                       Acarbose 50∼100 mg tid                       24
  [@B31]       Japan                       R, DB    20            49.7       60     6.9     25.7      None                                       Linagliptin 5 mg qd                       Voglibose 0.2 mg tid                         24
  [@B18]       Japan                       R        16            NA         NA     6       NA        None                                       Linagliptin 5 mg qd                       Voglibose 0.3 mg tid                         12

^1^The study by [@B32] included four groups of alogliptin treatment with different dosages, and these were included as four comparisons.

^2^The study by [@B16] included two groups of linagliptin treatment with different dosages, and these were included as four comparisons.

BMI, body mass index; OAD, oral antidiabetic drugs; DPP4, dipeptidyl peptidase-4; AGI, alpha-glucosidase inhibitors; R, randomized; DB, double blinded; NA, not available; qd, once daily; bid, twice daily; tid, three times daily.

###### 

Quality evaluation of the included studies *via* Cochrane's risk of bias tool.

           Random sequence generation   Allocation concealment   Blinding in performance   Blinding in outcome detection   Incomplete outcome data   Reporting bias   Other bias
  -------- ---------------------------- ------------------------ ------------------------- ------------------------------- ------------------------- ---------------- ------------
  [@B30]   Unclear                      Unclear                  Low                       Low                             Low                       Low              Unclear
  [@B13]   Low                          Unclear                  Low                       Low                             Low                       Low              Low
  [@B14]   Unclear                      Unclear                  Low                       Low                             Low                       Low              Low
  [@B32]   Unclear                      Unclear                  Low                       Low                             Low                       Low              Low
  [@B16]   Unclear                      Unclear                  Low                       Low                             Low                       Low              Low
  [@B29]   Unclear                      Unclear                  High                      High                            Low                       Low              Low
  [@B26]   Unclear                      Unclear                  High                      High                            Low                       Low              Low
  [@B17]   Low                          Unclear                  High                      High                            Low                       Low              Low
  [@B22]   Unclear                      Unclear                  High                      High                            Low                       Low              Low
  [@B28]   Low                          Unclear                  High                      High                            Low                       Low              Low
  [@B36]   Unclear                      Unclear                  High                      High                            Low                       Low              Low
  [@B39]   Low                          Unclear                  High                      High                            Low                       Low              Low
  [@B25]   Low                          Unclear                  High                      High                            Low                       Low              Low
  [@B21]   Low                          Unclear                  High                      High                            Low                       Low              Low
  [@B8]    Unclear                      Unclear                  High                      High                            Low                       Low              Low
  [@B5]    Unclear                      Unclear                  High                      High                            Low                       Low              Low
  [@B31]   Unclear                      Unclear                  Low                       Low                             Low                       Low              Unclear
  [@B18]   Unclear                      Unclear                  High                      High                            Low                       Low              Unclear

Comparison Between DPP4 Inhibitors and AGIs on HbA1c in T2DM {#s3_3}
------------------------------------------------------------

All of the 22 comparisons reported the efficacy of DPP4 inhibitors *versus* AGIs on HbA1c changes in T2DM patients. Significant heterogeneity was detected among the included RCTs (*P* for Cochrane's *Q* test \< 0.001, *I* ^2^ = 77%). Pooled results with a random effect model showed that treatment with DPP4 inhibitors was associated with a significant lower reduction of HbA1c as compared with AGIs (WMD: −0.37%, 95% CI: −0.48 to −0.26, *p* \< 0.001; [**Figure 2A**](#f2){ref-type="fig"}). Subsequent subgroup analyses indicated a significant lower reduction of HbA1c in patients treated with DPP4 inhibitors than AGIs, which was independent of the study design, patient number of the included RCTs, HbA1c level at baseline, with or without background OADs, and follow-up durations (*P* for efficacies all \< 0.05; [**Table 3**](#T3){ref-type="table"}). Moreover, the results of stratified analyses indicated that the reduction of HbA1c by DPP4 inhibitors compared with AGIs was more remarkable in double-blinded studies than open-label trials (*P* for subgroup difference = 0.005), and in patients without background OADs than those with background OADs (*P* for subgroup difference = 0.01). In addition, a trend of lower reduction of HbA1c was observed in studies with longer follow-up duration (52 weeks) than those with shorter follow-up duration (*P* for subgroup difference = 0.07). Stratified analyses according to the specific medications of DPP4 inhibitors and AGIs used in the RCTs showed that the benefits of DPP4 inhibitors *versus* AGIs on HbA1c was significant in studies with alogliptin, linagliptin, and sitagliptin, but not significant in studies with saxagliptin or vildagliptin, while significant in studies with voglibose, but not significant in studies with acarbose or miglitol.

![Forest plots for the meta-analysis of the hypoglycemic efficacy between dipeptidyl peptidase-4 (DPP4) inhibitors and α-glucosidase inhibitors (AGIs) in type 2 diabetes mellitus (T2DM) patients: **(A)** effect of DPP4 inhibitors and AGIs on glycosylated hemoglobin (HbA1c); **(B)** effect of DPP4 inhibitors and AGIs on FBG; and **(C)** effect of DPP4 inhibitors and AGIs on PPG-2h.](fphar-10-00777-g002){#f2}

###### 

Subgroup analysis for the effects of DPP4i compared with AGI on HbA1c.

  Variables                        Datasets (patients)   WMD (95% CI)             *P* for subgroup effect   *I*^2^   *P* for subgroup difference
  -------------------------------- --------------------- ------------------------ ------------------------- -------- -----------------------------
  **Study design**                                                                                                   
   R, DB                           10 (2,301)            −0.52 \[−0.68, −0.35\]   \<0.001                   77%      
   R                               12 (1,690)            −0.24 \[−0.35, −0.13\]   \<0.001                   51%      0.005
  **Sample size**                                                                                                    
   \>100                           16 (3,689)            −0.40 \[−0.53, −0.27\]   \<0.001                   82%      
   ≤100                            6 (302)               −0.24 \[−0.40, −0.08\]   0.003                     17%      0.12
  **Baseline HbA1c (%)**                                                                                             
   \>7                             15 (3,349)            −0.41 \[−0.55, −0.27\]   \<0.001                   83%      
   ≤7                              7 (642)               −0.27 \[−0.39, −0.15\]   \<0.001                   7%       0.14
  **Background OADs**                                                                                                
   Yes                             9 (1,230)             −0.23 \[−0.36, −0.09\]   \<0.001                   61%      
   No                              13 (2,761)            −0.47 \[−0.62, −0.33\]   \<0.001                   75%      0.01
  **Follow-up duration (weeks)**                                                                                     
   ≤12                             8 (1,471)             −0.34 \[−0.47, −0.21\]   \<0.001                   47%      
   24∼26                           9 (1,980)             −0.25 \[−0.37, −0.13\]   \<0.001                   45%      
   52                              5 (540)               −0.63 \[−0.93, −0.32\]   \<0.001                   90%      0.07
  **DPP4i medications**                                                                                              
   Alogliptin                      4 (459)               −0.76 \[−0.89, −0.64\]   \<0.001                   19%      
   Linagliptin                     6 (960)               −0.32 \[−0.42, −0.22\]   \<0.001                   0%       
   Saxagliptin                     2 (562)               −0.08 \[−0.20, 0.05\]    0.22                      0%       
   Sitagliptin                     8 (969)               −0.31 \[−0.44, −0.19\]   \<0.001                   41%      
   Vildagliptin                    2 (1,041)             −0.35 \[−0.84, 0.14\]    0.16                      84%      \<0.001
  **AGI medications**                                                                                                
   Acarbose                        3 (1,223)             −0.08 \[−0.20, 0.03\]    0.16                      0%       
   Miglitol                        2 (62)                −0.21 \[−0.55, 0.14\]    0.24                      0%       
   Voglibose                       15 (2,476)            −0.47 \[−0.59, −0.34\]   \<0.001                   73%      \<0.001

WMD, weighed mean difference; CI, confidence interval; R, randomized; DB, double blinded; DPP4i, dipeptidyl peptidase-4 inhibitors; AGI, alpha-glucosidase inhibitors.

Comparison Between DPP4 Inhibitors and AGIs on FBG and PPG-2h in T2DM {#s3_4}
---------------------------------------------------------------------

Pooled results of 20 comparisons showed that treatment with DPP4 inhibitors was associated with a significantly lower reduction of FBG as compared with AGIs (WMD: −0.53 mmol/L, 95% CI: −0.74 to −0.32, *P* \< 0.001; [**Figure 2B**](#f2){ref-type="fig"}) with significant heterogeneity (*P* for Cochrane's *Q* test \< 0.001; *I* ^2^ = 71%). Moreover, we found that DPP4 inhibitors were associated with a significantly lower reduction of PPG-2h as compared with AGIs in T2DM patients (WMD: −0.60 mmol/L, 95% CI: −1.18 to −0.03, *P* = 0.04; [**Figure 2C**](#f2){ref-type="fig"}) with significant heterogeneity (*P* for Cochrane's *Q* test \< 0.001; *I* ^2^ = 85%).

Comparison Between DPP4 Inhibitors and AGIs on Body Weight, Symptomatic Hypoglycemia, and Risk of GIAEs {#s3_5}
-------------------------------------------------------------------------------------------------------

Meta-analysis with 19 comparisons showed that DPP4 inhibitors significantly increased body weight as compared with AGIs in T2DM patients (WMD: 0.34 kg, 95% CI: 0.06 to 0.61, *P* = 0.02; [**Figure 3A**](#f3){ref-type="fig"}) with significant heterogeneity (*P* for Cochrane's *Q* test \< 0.001; *I* ^2^ = 75%). We also found that DPP4 inhibitors did not significantly affect the risk of symptomatic hypoglycemia as compared with AGIs (RR: 0.96, 95% CI: 0.52 to 1.77, *P* = 0.90; [**Figure 3B**](#f3){ref-type="fig"}) without significant heterogeneity (*P* for Cochrane's *Q* test = 0.97; *I* ^2^ = 0%), while treatment with DPP4 inhibitors was associated with significantly reduced risk of any GIAEs as compared with AGIs (RR: 0.48, 95% CI: 0.32 to 0.71, *P* \< 0.001; [**Figure 3C**](#f3){ref-type="fig"}) with significant heterogeneity (*P* for Cochrane's *Q* test \< 0.001; *I* ^2^ = 68%).

![Forest plots for the meta-analysis of the safety outcomes between DPP4 inhibitors and AGIs in T2DM patients: **(A)** effect of DPP4 inhibitors and AGIs on body weight; **(B)** effect of DPP4 inhibitors and AGIs on the incidence of symptomatic hypoglycemia; and **(C)** effect of DPP4 inhibitors and AGIs on the incidence of any gastrointestinal adverse events (GIAEs).](fphar-10-00777-g003){#f3}

Publication Bias {#s3_6}
----------------

Funnel plots for meta-analyses of the effects on changes of HbA1c, FBG, PPG-2h, and body weight, and the risks of symptomatic hypoglycemia and any GIAEs, were presented in [**Figure 4A--F**](#f4){ref-type="fig"}, which were symmetric on visual inspection, indicating no significant publication biases. Results of Egger's regression tests also demonstrated no significance in publication biases (*P* for Egger's regression tests = 0.38, 0.52, 0.61, 0.58, 0.48, and 0.21 respectively).

![Funnel plots for the meta-analyses comparing the efficacy and safety outcomes between DPP4 inhibitors and AGIs in T2DM patients; **(A)** HbA1c; **(B)** FBG; **(C)** PPG-2h; **(D)** body weight; **(E)** symptomatic hypoglycemia; and **(F)** any GIAEs.](fphar-10-00777-g004){#f4}

Discussion {#s4}
==========

In this updated meta-analysis of 18 RCTs with 4,051 T2DM patients, we found that DPP4 inhibitors confer better glycemic control than AGIs, as evidenced by significantly reduced HbA1c, FBG, and PPG-2h by DPP4 inhibitors compared to AGIs. Moreover, treatment with DPP4 inhibitors is associated with much less GIAEs and unaffected hypoglycemia, but a modest increased body weight as compared with AGIs. These results indicate that for T2DM patients, DPP4 inhibitors are superior to AGIs for better glycemic control but lower risks of GIAEs.

A previous meta-analysis ([@B2]) including nine RCTs showed that treatment with DPP4 inhibitors was associated with a lower reduction of HbA1c and a less incidence of gastrointestinal discomfort as compared with AGIs, while the other meta-analysis ([@B9]) including 11 RCTs published up to 2016 showed that AGI treatment was associated with a significantly lower reduction in HbA1c than DPP4 inhibitors. Many related RCTs have been published since the previous meta-analyses ([@B28]; [@B8]; [@B21]; [@B25]; [@B5]; [@B18]; [@B31]), which were included in this updated meta-analysis. Our meta-analysis has a few strengths as compared with the previous meta-analysis of the similar topic ([@B2]). Firstly, our updated meta-analysis included 18 RCTs of 4,051 T2DM patients, which is much larger than those of the previous ones, which enables us to perform subgroup analyses to confirm the robustness of our findings regarding the superiority of DPP4 inhibitors on glycemic control over AGIs. Results of the subgroup analysis confirmed that treatment with the DPP4 inhibitors was associated with significantly reduced HbA1c as compared with AGIs. The superiority of glycemic control of DPP4 inhibitors over AGIs was independent of study design, patient number of the included RCTs, HbA1c level at baseline, with or without background OADs, and follow-up durations, indicating the stability of the findings. Secondly, results of our subgroup analysis also suggested some interesting findings. For example, we found that the reduction of HbA1c by DPP4 inhibitors compared with AGIs was more remarkable in double-blinded studies than open-label trials. Since open-label trials are vulnerable to various bias, these results indicated that the actual hypoglycemic efficacy of DPP4 inhibitors compared with AGIs may be stronger than the overall results (−0.30% in previous meta-analysis and−0.37% in our study). In addition, we found a trend of lower reduction of HbA1c by DPP4 inhibitors compared with AGIs in studies with longer follow-up duration (52 weeks) than those with shorter follow-up duration. These results suggest the optimal durability of the hypoglycemic efficacy of DPP4 inhibitors. Thirdly, we found that despite of significant decreased FBG by DPP4 inhibitors compared with AGIs, treatment with DPP4 inhibitors also significantly decreased PPG as compared with AGIs in T2DM patients, which is not reported in previous meta-analysis ([@B2]). This is of clinical significance since AGIs are often considered as the OADs of choice to lower PPG because of its direct pharmacological action, which is to inhibit the absorption of carbohydrates during the meals ([@B19]; [@B33]). Based on our results, DPP4 inhibitors should be considered in patients with high PPG levels. Moreover, meal intake--related glycemic excursion has been recognized as an important contributor to glycemic variability, which has been validated as another risk factor for morbidity and mortality in T2DM patients independent of glycemic control ([@B10]; [@B27]). Therefore, our finding indicated that DPP4 inhibitors may be an alternative category of OADs to stabilize glycemic variability, although studies are needed to confirm our findings.

The potential mechanisms underlying the potential superiority of DPP4 inhibitors on glycemic control to AGIs may be primarily explained by the differences of the pharmacological mechanisms of the two categories of OADs. As mentioned previously, the AGIs mainly lower the PPG *via* inhibiting the absorption of carbohydrates during the meal ([@B19]). However, DPP4 inhibitors could exert both the fasting and postprandial hypoglycemic efficacies *via* reducing glucagon secretion during fasting and stimulating the glucose-dependent insulin secretion during the meal ([@B3]). Besides, DPP4 inhibitors may also be associated with better patient compliance, since most DPP4 inhibitors are to be taken once daily, while all of the AGIs are to be taken three times daily. This could be an alternative mechanism underlying the better glycemic control as observed in patients taking DPP4 inhibitors compared to those taking AGIs.

Our results confirmed the findings of the previous studies that treatment with DPP4 inhibitors in T2DM patients is associated with significantly decreased risk of GIAEs and unaffected hypoglycemia, but a moderate increased body weight as compared with AGIs ([@B2]; [@B38]). Because high incidence of GIAEs is a common reason for the discontinuation of AGIs in T2DM patients, based on our findings, DPP4 inhibitors should be recommended to patients who are unable to tolerate AGIs as an initial therapy for T2DM or in combination with other OADs. The mechanisms underlying the unaffected risk of hypoglycemia in patients taking DPP4 inhibitors as compared with those taking AGIs may rely on the glucose-dependent insulin stimulatory effect of DPP4 inhibitors ([@B7]; [@B35]). Moreover, the modest effect of body weight gain in DPP4 inhibitors as compared with AGIs could be explained by the increased GIP level after treatment of DPP4 inhibitors. The GIP has been recognized as a peptide which could enhance the uptake of lipids into the adipocytes in the overnutrition condition ([@B34]). However, from our point of view, the gain of body weight after treatment with DPP4 inhibitors as compared with AGIs is moderate (0.34 kg), which does not outweigh the potential benefits of DPP4 inhibitors on glycemic control and GIAE risk.

Our study has limitations. Firstly, significant heterogeneities exist for meta-analysis comparing the efficacies of DPP4 inhibitors and AGIs on HbA1c, FBG, PPG-2h, body weight, and incidence of GIAEs. The differences of study characteristics, such as the baseline HbA1c, T2DM durations, comorbidities, and concurrent medications including OADs, may contribute to the heterogeneities. While the influences of these factors could not be determined since the stratified outcomes according to the above characteristics were not reported in the included RCTs. Moreover, we performed the meta-analysis on the study level instead of on the individual patient level because we did not have access to the individual patient data. This prevented us from performing intensified analyses of the heterogeneity. In addition, as compared with AGIs, the influences of DPP4 inhibitors on clinical outcomes, such as incidences of cardiovascular events and overall mortality, remained to be determined. Finally, the findings of the meta-analysis were almost all based on the RCTs in Asian patients. Since carbohydrates account for a larger proportion of diet structures of the Asians, AGIs are often prescribed in Asian T2DM patients ([@B40]). Whether DPP4 inhibitors are superior to AGIs in glycemic control in other ethnic group should be investigated in the future.

Conclusions {#s5}
===========

In conclusion, our meta-analysis showed that DPP4 inhibitors are superior to AGIs in T2DM patients for better glycemic control but lower risks of GIAEs.
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